<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bills LA</submitter><funding>U.S. Department of Energy</funding><pagination>41057</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12635120</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Terbium-149g ([Formula: see text] = 4.12 h) is of particular interest for targeted alpha therapy cancer treatment due to its ability to decay via both alpha and positron emission, making it a potential theranostic nuclide. Due to many challenges facing its production, there are limited facilities worldwide that have demonstrated the ability to produce this nuclide in quantities sufficient for medical research. Since the Cyclotron Institute at Texas A&amp;M University is a specialized accelerator facility capable of accelerating a wide variety of ions, we are investigating production pathway options. One of the major challenges facing its production is the known co-production of the excited isomeric state, [Formula: see text]Tb ([Formula: see text] = 4.1 min). However, this state does not decay</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Cross sections of [Formula: see text]Sm([Formula: see text]Li,x) reactions for the production of [Formula: see text]Tb for targeted alpha therapy.</pubmed_title><pmcid>PMC12635120</pmcid><funding_grant_id>DE-SC0022550</funding_grant_id><funding_grant_id>DE-SC0020958</funding_grant_id><funding_grant_id>DE-FG02-93ER40773</funding_grant_id><pubmed_authors>Harvey BM</pubmed_authors><pubmed_authors>Rojas DC</pubmed_authors><pubmed_authors>Abbott AD</pubmed_authors><pubmed_authors>Mohs C</pubmed_authors><pubmed_authors>Bills LA</pubmed_authors><pubmed_authors>Santucci J</pubmed_authors><pubmed_authors>Thomas D</pubmed_authors><pubmed_authors>Yennello SJ</pubmed_authors><pubmed_authors>Tobin Z</pubmed_authors><pubmed_authors>Rider R</pubmed_authors><pubmed_authors>Tamashiro AS</pubmed_authors><pubmed_authors>Sorensen M</pubmed_authors><pubmed_authors>Vermeulen CE</pubmed_authors><pubmed_authors>Hankins T</pubmed_authors><pubmed_authors>Harke JT</pubmed_authors><pubmed_authors>McIntosh LA</pubmed_authors><pubmed_authors>McIntosh AB</pubmed_authors><pubmed_authors>Hagel K</pubmed_authors><pubmed_authors>Mishnayot Y</pubmed_authors><pubmed_authors>Garcia-Duarte J</pubmed_authors><pubmed_authors>Reuter M</pubmed_authors><pubmed_authors>Picayo GA</pubmed_authors><pubmed_authors>Hughes RO</pubmed_authors><pubmed_authors>Morrell JT</pubmed_authors><pubmed_authors>Sauceda S</pubmed_authors><pubmed_authors>Gott MD</pubmed_authors><pubmed_authors>Tereshatov EE</pubmed_authors><pubmed_authors>Adsley P</pubmed_authors><pubmed_authors>Wellons B</pubmed_authors><pubmed_authors>Tabacaru A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cross sections of [Formula: see text]Sm([Formula: see text]Li,x) reactions for the production of [Formula: see text]Tb for targeted alpha therapy.</name><description>Terbium-149g ([Formula: see text] = 4.12 h) is of particular interest for targeted alpha therapy cancer treatment due to its ability to decay via both alpha and positron emission, making it a potential theranostic nuclide. Due to many challenges facing its production, there are limited facilities worldwide that have demonstrated the ability to produce this nuclide in quantities sufficient for medical research. Since the Cyclotron Institute at Texas A&amp;M University is a specialized accelerator facility capable of accelerating a wide variety of ions, we are investigating production pathway options. One of the major challenges facing its production is the known co-production of the excited isomeric state, [Formula: see text]Tb ([Formula: see text] = 4.1 min). However, this state does not decay</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T19:44:02.564Z</modification><creation>2026-05-21T03:10:58.983Z</creation></dates><accession>S-EPMC12635120</accession><cross_references><pubmed>41266663</pubmed><doi>10.1038/s41598-025-24894-9</doi></cross_references></HashMap>